Sign In
Buy MASI
$179.95
+0 (+0%)
At Close: Jun 23, 2026
Masimo (MASI) Tops Q2 Earnings and Revenue Estimates
07:09pm, Tuesday, 27'th Jul 2021
Masimo (MASI) delivered earnings and revenue surprises of 3.30% and 2.92%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
MedTech Thrives on Healthcare IT in 2021: 4 Stocks to Focus on
10:09am, Friday, 16'th Jul 2021
Health IT stocks like HealthEquity (HQY), Veeva Systems (VEEV), Tabula Rasa (TRHC) and Allscripts (MDRX) are expected to continue their run over the next few months.
Masimo (MASI) Reports Study Findings Backing the SedLine
12:02pm, Thursday, 08'th Jul 2021
Masimo (MASI) releases new study findings assessing two parameters provided by the SedLine that exhibit high predictability for mortality 180 days after cardiac arrest.
NEUCHATEL, Switzerland--(BUSINESS WIRE)--A new study found that the combination of two Masimo SedLine® parameters had high predictability for mortality 180 days after cardiac arrest.
Masimo's (MASI) Wearable Wireless Thermometer Gets FDA Nod
12:02pm, Tuesday, 22'nd Jun 2021
Masimo's (MASI) continuous, wearable thermometer is likely to help monitor and track body temperature in all thermometer applications following the FDA's clearance.
Masimo's Wearable Thermometer Scores FDA Approval For Prescription, OTC Use
11:23am, Monday, 21'st Jun 2021
Masimo (NASDAQ: MASI) has announced that Radius Tº, a wearable, wireless thermometer, has received FDA 510(k) clearance for both prescription and over-the-counter (OTC) use on patients and consume
Masimo's (MASI) ORi-Guided OLV Procedure Favored by New Study
11:17am, Wednesday, 16'th Jun 2021
Masimo's (MASI) ORi-guided thoracic anesthesia procedure is likely to reduce hospital stay and increase patient safety.
New Study Investigates the Impact of ORi-Guided Oxygen Titration on Hyperoxemia-Mediated Morbidity During One-Lung Ventilation
02:00am, Monday, 14'th Jun 2021
NEUCHATEL, Switzerland--(BUSINESS WIRE)--A new study found that oxygen titration guided by Masimo ORi™ may reduce hospital stay and increase patient safety.
Masimo (MASI) Down 4.6% Since Last Earnings Report: Can It Rebound?
12:02pm, Wednesday, 26'th May 2021
Masimo (MASI) reported earnings 30 days ago. What's next for the stock?
BIGZ: Holdings Updated - Great Diversifier Into Growth Names
03:27pm, Monday, 24'th May 2021
BIGZ launched late in March, they have finally updated their holdings to include the top ten.
Masimo to Present in UBS Global Healthcare Virtual Conference
04:05pm, Wednesday, 19'th May 2021
IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced that its management is scheduled to participate in the UBS Global Healthcare Virtual Conference on Wednesday, May 26, 2021 at 2:0
Masimo (MASI), Spacelabs Team Up to Enhance Patient Outcome
10:31am, Tuesday, 18'th May 2021
Masimo's (MASI) extension of partnership with Spacelabs is expected to provide better patient outcomes with the accessibility of patient monitoring solutions.
New Study Assesses the Effects of Masimo Patient SafetyNet™ on Nursing Workflows in the General Ward
02:00am, Monday, 17'th May 2021
NEUCHATEL, Switzerland--(BUSINESS WIRE)--A study evaluating Masimo Patient SafetyNet™ found that it reduced postoperative respiratory assessment nursing workload by more than 60%.
Study Investigates the Ability of Masimo O3® to Aid in Monitoring Septic Shock ICU Patients and Predicting Mortality
02:00am, Monday, 10'th May 2021
NEUCHATEL, Switzerland--(BUSINESS WIRE)--A new study found that Masimo O3® Regional Oximetry may aid in monitoring septic shock patients and may have value as a predictor of mortality.
Study Investigates the Ability of Masimo PVi® to Predict Preload Responsiveness in Patients On Nasal High-Flow Therapy
02:00am, Monday, 03'rd May 2021
NEUCHATEL, Switzerland--(BUSINESS WIRE)--Masimo announced the findings of the first study to evaluate the utility of PVi® on patients treated with nasal high-flow therapy.
